120
Participants
Start Date
Not specified
Study Completion Date
August 31, 1998
Doxorubicin hydrochloride (liposomal)
Filgrastim
Bleomycin sulfate
Vincristine sulfate
Memorial Sloan-Kettering Cancer Ctr., New York
SUNY - Buffalo, Erie County Medical Ctr., Buffalo
Univ. of Miami AIDS CRS, Miami
Alabama Therapeutics CRS, Birmingham
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis
Northwestern University CRS, Chicago
Rush Univ. Med. Ctr. ACTG CRS, Chicago
Washington U CRS, St Louis
University of Colorado Hospital CRS, Aurora
USC CRS, Los Angeles
UCLA CARE Center CRS, Los Angeles
Queens Med. Ctr., Honolulu
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu
Ucsf Aids Crs, San Francisco
Massachusetts General Hospital ACTG CRS, Boston
Bmc Actg Crs, Boston
Beth Israel Deaconess - East Campus A0102 CRS, Boston
Collaborators (1)
Sequus Pharmaceuticals
INDUSTRY
Amgen
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH